Researchers identify key metabolic regulators of drug resistance in the fight against pancreatic cancer

Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk

Researchers from the University at Buffalo School of Pharmacy and Pharmaceutical Sciences recently published in Molecular & Cellular Proteomics, describing their work in identifying key metabolic regulators involved in cancer cell resistance to gemcitabine (Gem), a standard-of-care chemotherapy for pancreatic dual adenocarcinoma (PDAC), the most lethal type of pancreatic cancer.

What’s behind the amoxicillin shortage? A pharmacist explains

Previous article

Virginia Tech researchers receive three grants to study the effects of ultra-processed foods

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations